Cerebral Amyloid Angiopathy With a Hypomanic Episode Treated With Valproic Acid

Naomichi Okamoto 1, Atsuko Ikenouchi 1, Issel Seki 2, Natsumi Hirano 3, Reiji Yoshimura 2

1. Medical Center for Dementia, University Hospital/Psychiatry, University of Occupational and Environmental Health, Kitakyushu, JPN 2. Psychiatry, University of Occupational and Environmental Health, Kitakyushu, JPN 3. Radiology, University of Occupational and Environmental Health, Kitakyushu, JPN

Corresponding author: Atsuko Ikenouchi, atsuko-i@med.ueh-u.ac.jp

Abstract

Cerebral amyloid angiopathy (CAA) is a major cause of spontaneous intracerebral hemorrhage in the elderly. There are no reports of CAA causing mania or hypomanic episodes, and the incidence of mania or hypomanic episodes in patients with vascular dementia is generally considered to be rare. Here, we present a case of CAA with hypomania in which valproic acid (VPA) led to improvement in the symptoms of hypomania. An 80-year-old, right-handed Japanese woman with mild cognitive impairment (MCI) presented with a hypomanic episode. Her brain magnetic resonance imaging showed multiple obsolete infarcts and hemorrhages caused by CAA. We diagnosed her as suffering from a hypomanic episode in MCI associated with CAA and started VPA 400 mg/day for seven weeks. Her hypomanic episode gradually improved on VPA. This case indicates that VPA can be useful in the treatment of hypomanic episodes in MCI associated with CAA.

Introduction

Cerebral amyloid angiopathy (CAA) is characterized by the accumulation of amyloid fibrils in the walls of small to medium-sized arterial blood vessels, central nervous system parenchyma, and leptomeningeal capillaries. CAA is a major cause of spontaneous intracerebral hemorrhage in the elderly and is an important factor in age-related cognitive decline [1]. While CAA is a frequent pathological change in Alzheimer’s disease (AD), it is sometimes treated as an independent clinical entity. The sentinel clinical presentations of CAA include cognitive impairment and dementia and transient focal neurological episodes often associated with acute convexity subarachnoid hemorrhage or cortical superficial siderosis [2]. Regarding cognitive impairment, which is a common symptom, compared to AD, patients with CAA have better memory retention, but a marked decline in executive function and processing speed, which is similar to symptoms seen in vascular dementia [3]. To date, mania or hypomanic state caused by CAA with mild cognitive impairment (MCI) has not been reported. Here, we present a case of a hypomanic episode in MCI associated with CAA. To the best of our knowledge, this is the first report to show the efficacy of valproic acid (VPA) to treat hypomanic episodes in MCI associated with CAA.

Case Presentation

An 80-year-old, right-handed Japanese woman made an outpatient visit to our university hospital. Her initial symptoms were poor judgment, low concentration, and personality changes, which started at the age of 79. She had a physical history of hypertension and uterine fibroids. She had no personal or family history of psychiatric diseases, such as depression or mania. She was able to maintain her daily life, and her Mini-Mental State Examination-Japanese (MMSE-J) score was 29/30 points. There were no obvious neurological findings. A head computed tomography (CT) was performed which showed mild atrophy of the bilateral cerebrum, old infarcts in the left basal ganglia, and deep white matter of the left frontal lobe. As a result, dementia was ruled out and she was diagnosed with MCI. She was kept on observation without anti-dementia drugs; however, gradually, she became irritative. At the age of 80, her family noticed her hypomanic episodes such as verbosity, flight of ideas, hypertrophy of self-esteem, mood swings, irritability, excessive energy, and distraction. There was no decrease in the desire for sleep, sexual hyperactivity, or fanciful dressing. As a result, her family brought her to our hospital again. At this time, her MMSE-J score was 27/30 points, Montreal Cognitive Assessment-Japan (MoCA-J) score was 19/30 points, and Young Mania Rating Scale (YMRS) score was 25/60 points. There was no visual hallucination, muscle rigidity, parkinsonism, antisocial, and homophbic behavior. Hematological and biochemical examinations as well as thyroid function were normal. Her brain magnetic resonance imaging (MRI) showed diffuse cerebral atrophy involving the medial temporal lobe. T2-weighted image/fluid-attenuated inversion recovery (T2WI/FLAIR) showed a high signal intensity in the bilateral cerebral white matter, indicating chronic ischemic changes due to lacunar infarction (Figure 1A). In addition, T2WI showed low signal intensity in bilateral temporal lobes, occipital lobes, right subcortical frontal lobes, and right illuminating hemisphere, indicating obsolete

How to cite this article
Okamoto N, Ikenouchi A, Seki I, et al. (July 15, 2021) Cerebral Amyloid Angiopathy With a Hypomanic Episode Treated With Valproic Acid. Cureus 13(7): e16411. DOI 10.7759/cureus.16411
microbleeds and CAA from the distribution (Figure 1B). The patient was diagnosed with probable CAA according to the Boston criteria [4], along with a hypomanic episode in the setting of MCI associated with CAA. We started her on VPA 400 mg/day for the hypomanic episode. Her hypomanic episode was gradually improved, and her YMRS score decreased to 8/60 points seven weeks after VPA was initiated. Her blood level of VPA was 43.1 µg/mL. Although she still has some symptoms of MCI and mild verbosity, she does not worry about her daily living and continues to visit our outpatient department.

![Figure 1A](image1.png) ![Figure 1B](image2.png)

**FIGURE 1: Brain MRI.**

(A) High signal intensity can be seen in the bilateral cerebral white matter, indicating chronic ischemic changes on T2WI/FLAIR. (B) Low signal intensity can be seen in bilateral temporal lobes, occipital lobes, right subcortical frontal lobes, and right illuminating hemisphere, indicating obsolete microbleeds and CAA on T2WI.

CAA: cerebral amyloid angiopathy; T2WI: T2-weighted image; FLAIR: fluid-attenuated inversion recovery

**Discussion**

The following two important findings were noted in this case: MCI from CAA can present as a hypomanic episode, and VPA can be effective in the treatment of the hypomanic episode associated with CAA. The frequency of mania in patients with vascular dementia is generally considered to be rare, for example, in a study involving 500 consecutive stroke patients, there were only two cases of mania [5]. In other studies, patients had a history of bipolar disorder [6] or were on antidepressant drugs [7]. Strong evidence shows that VPA is effective in mania of bipolar disorder [8]. On the other hand, a systematic meta-analysis found insufficient evidence to support VPA to treat dementia for cognitive, psychiatric, or disease-modifying symptoms [9]. Therefore, in this case, the symptoms were indeed related to mania rather than personality changes associated with behavioral and psychological symptoms of dementia.

CAA is caused by the accumulation of amyloid-β protein in the walls of cortical and leptomeningeal arteries [1]. Lobar microbleeds are a hallmark of the disease, which were also observed in this case [10]. Although frequently associated with AD, CAA also independently contributes to cognitive impairment [11]. The Boston criteria are non-invasive radiological criteria [4] to differentiate and diagnose CAA. We used history, MoCA-J, and MMSE-J to rule out AD in this patient. Classically, Starkstein and Robinson reported that post-stroke mania is strongly associated with both a right hemisphere lesion in a limbic-connected area and a second predisposing factor, such as genetic loading for affective disorder, pre-existing subcortical atrophy, or seizure disorder [12]. In our case, T2WI showed low single intensity right subcortical frontal lobes and right illuminating hemisphere. VPA can potentiate the inhibitory effect of γ-aminobutyric acid (GABA) transmission, possibly by enhancing GABA synthesis and blocking metabolism [13]. In this case, VPA was effective in treating hypomania due to CAA as well as bipolar disorder, suggesting that it reinforces the pathology that mania is the result of neuroexcitatory conduction due to abnormal brain function. In addition, VPA suppresses inflammatory cytokines such as interleukin-1beta and tumor necrosis factor-alpha [14] and reduces amyloid-β oligomers, leading to loss of synaptic proteins from the neuron [15]. Hence, VPA can have an additional and different pharmacological effect on amyloid to improve amyloid-β deposition.

There are several limitations to this study. CAA and AD cannot be definitively diagnosed without a pathological autopsy. In our case, T2WI showed low signal intensity in the right illuminating hemisphere as well as bilateral temporal lobes.
Conclusions

We presented the case of an 80-year-old, right-handed Japanese woman with MCI caused by CAA. She presented with a hypomanic episode, and VPA was effective in the treatment of the disease. To the best of our knowledge, this is the first report of MCI from CAA that presented with a hypomanic episode, even though there was no history of bipolar disorder or antidepressant drug use. Second, VPA can be useful in the treatment of hypomanic episodes. Further studies should be conducted to confirm the effectiveness of VPA.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Gatti L, Tinelli F, Scelzo E, et al.: Understanding the pathophysiology of cerebral amyloid angiopathy. Int J Mol Sci. 2020, 21:3435. 10.3390/ijms21103435
2. Charidimou A, Boullouis G, Gurrol ME, et al.: Emerging concepts in sporadic cerebral amyloid angiopathy. Brain. 2017, 140:1829-50. 10.1093/brain/awx047
3. Case NF, Charlton A, Zwers A, et al.: Cerebral amyloid angiopathy is associated with executive dysfunction and mild cognitive impairment. Stroke. 2016, 47:2010-6. 10.1161/STROKEAHA.116.012999
4. Knudsen KA, Rosand J, Karluk D, Greenberg SM: Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001, 56:537-9. 10.1212/wnl.56.4.537
5. Robinson RG, Boston JD, Starkstein SE, Price TR: Comparison of mania and depression after brain injury: causal factors. Am J Psychiatry. 1988, 145:172-8. 10.1176/ajp.145.2.172
6. Watanabe Y, Shioiri T, Kibune H, Someya T: Mania after vascular dementia in a patient with bipolar II disorder. Psychiatry Clin Neurosci. 2006, 60:117-8. 10.1111/j.1440-1819.2006.01470.x
7. Starkstein SE, Boston JD, Robinson RG: Mechanisms of mania after brain injury. 12 case reports and review of the literature. J Nerv Ment Dis. 1988, 176:87-100. 10.1097/00005053-198802000-00004
8. Yatham LN, Kennedy SH, Parikh SV, et al.: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018, 20:97-170. 10.1111/bdi.12669
9. Liu J, Wang LN: Efficacy and safety of valproic acid in dementia: a systematic review with meta-analysis. Arch Gerontol Geriatr. 2020, 89:104091. 10.1016/j.archger.2020.104091
10. Martinez-Ramirez S, Romero JR, Shooamanesh A, et al.: Diagnostic value of lobar microbleeds in individuals without intracerebral hemorrhage. Alzheimers Dement. 2015, 11:1480-8. 10.1016/j.jalz.2015.04.009
11. Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA: Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol. 2011, 69:520-7. 10.1002/ana.22112
12. Starkstein SE, Robinson RG: Affective disorders and cerebral vascular disease. Br J Psychiatry. 1989, 154:170-82. 10.1192/bjp.154.2.170
13. Owens MJ, Nemeroff CB: Pharmacology of valproate. Psychopharmacol Bull. 2005, 37 Suppl 2:17-24.
14. Xuan AG, Pan XB, Wei P, et al.: Valproic acid alleviates memory deficits and attenuates amyloid-β deposition in transgenic mouse model of Alzheimer’s disease. Mol Neurobiol. 2015, 51:300-12. 10.1007/s12035-014-8751-4
15. Williams RS, Bate C: Valproic acid and its congener propylisopropylacetic acid reduced the amount of soluble amyloid-β oligomers released from 7PA2 cells. Neuropharmacology. 2018, 128:54-62. 10.1016/j.neuropharm.2017.09.051